Zalicus Inc. – Product Pipeline Review – H2 2011

Date: September 1, 2011
Pages: 73
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: Z1510C5E1E0EN
Leaflet:

Download PDF Leaflet

Zalicus Inc. – Product Pipeline Review – H2 2011
Zalicus Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Zalicus Inc. – Product Pipeline Review – H2 2011” provides data on the Zalicus Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Zalicus Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Zalicus Inc. and industry–specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Zalicus Inc.
  • Brief Zalicus Inc. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Zalicus Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Zalicus Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Zalicus Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate Zalicus Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Zalicus Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Zalicus Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Zalicus Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Zalicus Inc. and identify potential opportunities in those areas.
Zalicus Inc. Snapshot
Zalicus Inc. Overview
Key Information
Key Facts
Zalicus Inc. – Research and Development Overview
Key Therapeutic Areas
Zalicus Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Zalicus Inc. – Pipeline Products Glance
Zalicus Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Zalicus Inc.–Early Stage Pipeline Products
Discovery Products/Combination Treatment Modalities
Zalicus Inc. – Drug Profiles
CRx-102
Product Description
Mechanism of Action
R&D Progress
CRx-601
Product Description
Mechanism of Action
R&D Progress
Oncology Program
Product Description
Mechanism of Action
R&D Progress
Zalicus Inc. - Pipeline Products By Target
Zalicus Inc. – Pipeline Products by Route of Administration
Zalicus Inc. – Pipeline Products by Molecule Type
Zalicus Inc. – Recent Pipeline Updates
Zalicus Inc. - Dormant Projects
Zalicus Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
CRx-139
CRx-150
Zalicus Inc. – Company Statement
Zalicus Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jun 30, 2006: CombinatoRx Drug Candidate CRx-102 Demonstrates Positive Phase 2 Study Results In Hand Osteoarthritis
Nov 29, 2010: Zalicus To Present Data On A2A Agonist Oncology Program At ASH Annual Meeting
Jun 29, 2011: Zalicus Initiates Phase IIb Clinical Trial Of Synavive In Rheumatoid Arthritis
Mar 29, 2011: Zalicus Receives Composition-of-Matter Patent For Synavive
Oct 27, 2008: CombinatoRx Provides In-Depth Analysis From Phase 2b Knee Osteoarthritis Study Of Synavive (CRx-102) With Clinical Investigators
May 27, 2009: CombinatoRx Reports Positive Phase II Trial Results For CRx-401
May 27, 2008: CombinatoRx Completes Enrollment In Phase 2B Clinical Trial Of CRx-102 In Knee Osteoarthritis
May 27, 2008: CombinatoRx Completes Enrollment In Phase 2B Clinical Trial Of CRx-102 In Knee Osteoarthritis
Sep 26, 2007: CombinatoRx Announces Initiation Of Phase 2b Clinical Study Of CRx-102 In Knee Osteoarthritis
Apr 26, 2010: Covidien Launches EXALGO Extended-Release Tablets
Mar 26, 2007: CombinatoRx Provides Topline Results From Phase II RA Study With CRx-139 And Very Low Dose Prednisolone
Oct 25, 2007: CombinatoRx Publishes Clinical Study Results Of CRx-102 In Hand Osteoarthritis
Feb 25, 2011: Zalicus Publishes Data On Sodium Channel Compound In Pain Models
May 22, 2006: CombinatoRx Reports Second Positive Phase 2 Study with CRx-102
May 22, 2006: CombinatoRx Reports Second Positive Phase 2 Study With CRx-102
Feb 22, 2006: CombinatoRx Discontinues CRx-140 as an Oral Product Candidate For Psoriasis; Trial Does Not Show Statistical Significance in Pre-Specified Endpoints
Oct 21, 2009: CombinatoRx's Synavive (CRx-102) Maintains Efficacy Throughout 12 Month Phase 2 Knee OA Extension Trial
Oct 21, 2009: CombinatoRx'S Synavive (CRx-102) Maintains Efficacy Throughout 12 Month Phase 2 Knee OA Extension Trial
Apr 18, 2006: CombinatoRx Reports Positive Results For CRx-170 In Phase 2 Proof-of-Concept Asthma Clinical Trial
Jul 17, 2007: CombinatoRx's CRx-150 Fails to Meet Product Profile in Phase II Trial in RA; Development Discontinued in Favor of CRx-102
Feb 16, 2010: CombinatoRx Announces Extension Of Exalgo Extended Release Tablets PDUFA Date
Aug 14, 2007: CombinatoRx Announces Initiation Of Phase IIa Proof-Of-Concept Clinical Study With CRx-401 For Type 2 Diabetes
Jun 13, 2006: Additional Clinical Data On CombinatoRx Drug Candidate CRx-102 Presents At Upcoming EULAR Meeting
Jun 12, 2006: Combinatorx Drug Candidate CRx-102 Demonstrates Statistically Significant Improvement In Pain And Other Clinical Measures
Jun 12, 2006: CombinatoRx Presents Preclinical Data On CRx-401
Mar 12, 2008: CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results in Psoriasis
Jun 11, 2009: Neuromed Pharmaceuticals Announces that Merck Terminates Research Collaboration and License Agreement for Compounds Targeting N-Type Calcium Channels
Nov 06, 2006: CombinatoRx Drug Candidate CRx-102 Demonstrates Positive Phase 2 Results In Rheumatoid Arthritis
Nov 06, 2006: CombinatoRx Drug Candidate CRx-102 Demonstrates Positive Phase 2 Results In Rheumatoid Arthritis
Oct 06, 2008: CombinatoRx Announces Top-Line Results From Phase 2b Study Of Synavive (CRx-102) For Knee Osteoarthritis
Mar 03, 2010: CombinatoRx Wins FDA Approval For Exalgo Extended-Release Tablets
Financial Deals Landscape
Zalicus Inc., Deals Volume Summary, 2004 to YTD 2011
Zalicus Inc., Deals Summary By Region, 2004 to YTD 2011
Zalicus Inc., Deals Summary, 2004 to YTD 2011
Zalicus Inc. Detailed Deal Summary
Merger
CombinatoRx Completes Merger With Neuromed
Venture Financing
CombinatoRx Secures $30 Million In Third Round Of Financing
Equity Offering
CombinatoRx Completes Private Placement Of $35 Million
CombinatoRx Completes Private Placement Of $48 Million
CombinatoRx Completes Initial Public Offering Of $48 Million
CombinatoRx Enters Into Research Collaboration With Charley's Fund And THE NASH AVERY
CombinatoRx Signs An Agreement With Cystic Fibrosis Foundation Therapeutics
CombinatoRx Signs Agreement With Fovea Pharmaceuticals
CombinatoRx Enters Into Research Agreement With CHDI
CombinatoRx Enters Into Co-Development Agreement With ABC2
Licensing Agreements
Clinical Data Enters Into License Agreement With CombinatoRx
CombinatoRx Enters Into Licensing Agreement With Novartis Institutes For BioMedical Research
Angiotech Pharmaceuticals Extends Licensing Agreement With CombinatoRx
CombinatoRx Enters Into Research And Licensing Agreement With Angiotech Pharmaceuticals
CombinatoRx Enters Into Licensing Agreement With HenKan Pharmaceutical
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Zalicus Inc. – Pipeline by Therapy Area and Indication, H2 2011
Zalicus Inc. – Pipeline by Stage of Development, H2 2011
Zalicus Inc. – Monotherapy Products in Pipeline, H2 2011
Zalicus Inc. - Phase II, H2 2011
Zalicus Inc. - Phase I, H2 2011
Zalicus Inc. - Pipeline By Target, H2 2011
Zalicus Inc. – Pipeline By Route of Administration, H2 2011
Zalicus Inc. – Pipeline By Molecule Type, H2 2011
Zalicus Inc. – Recent Pipeline Updates, H2 2011
Zalicus Inc. - Dormant Developmental Projects, 2010
Zalicus Inc. - Discontinued Pipeline Products, 2010
Zalicus Inc., Subsidiaries
Zalicus Inc., Deals Summary, 2004 to YTD 2011
Zalicus Inc., Deals Summary by Region, 2004 to YTD 2011
Zalicus Inc., Deals Summary, 2004 to YTD 2011

LIST OF FIGURES

Zalicus Inc. – Pipeline by Therapy Area and Indication, H2 2011
Zalicus Inc. – Pipeline by Stage of Development, H2 2011
Zalicus Inc. – Monotherapy Products in Pipeline, H2 2011
Zalicus Inc. – Pipeline By Molecule Type, H2 2011

Ask Your Question

Zalicus Inc. – Product Pipeline Review – H2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: